Rectal Absorption of Omeprazole from Syppositories in Rabbits

  • Published : 1995.08.01

Abstract

Rectal absorption of opeprazole, a proton pump inhibitor, from suppositories was studied in rabbits. The suppositories were prepared by the conventional melting method with two types of bases, water-soluble polyethylene glycol (PEG) 4000 and oil-soluble Witepsol H15 bases, and administered intractally (ir) to rabbits at a dose of 10 mg omeprazole/kg. The plasma omeprazole concentration-time profiles of the two suppositories were compared with those following intravenous 9iv) administration of the same dose. There were no significant differences between the two suppositories in bioabailabilities and peak plasma concentrations $(C_{max})$. Bioavaiabilities and $C_{max}$ of PEG- and Witpsol suppositories were 30.3 and 33.9%, and 7.0 and $5.6\mug/ml$, resepectively. However, PEG suppository showed significantly (p<0.05) shorter time to reach peak plasma concentration $(T_{max})$ mean absorption time (MAT) and mean residence time in the plasma (MRT) than Witepsol suppository. The $T_{max}$ MRT nad MAT were 25.0, 83.0 and 38.5 min for PEG syppository, but were 90.0, 122.5 and 78.0 min for Wiepsol supposiotory, respectively. These differences between thw two suppositories could be explanined by the difference in the in vitro dissolution rates between the suppositories. The dissolution of omeprazole form PEG suppository was reportedly much faster than that from Witepsol suppository. It suggests that plasma profiles of omeprazole, especially $C_{max}$ MAT and MRT, could be controlled by modifying the in vitro dissolution rate of the drug from the suppositories. Above results suggest that rectal suppository is worth developing as an alternative dosage form of omeprazole to the conventional oral preparations which need sophisticated treatments, such as enterix coating, to prevent acid degradation of the drug in the stomach fluid.

Keywords

References

  1. J. Chromatogr. v.426 Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography Amantea,M.A.;Narang,P.K.
  2. Chem. Pharm. Bull. v.17 Complications in using rabbits for the study of oral drug absorption Chiou,W.L.;Riegelman,S.;Amberg,J.R.
  3. Arch. Pharm. Res. v.18 Bioavailabilities of omeprazole administered to rats through various routes Choi,M.S.;Lee,Y.H.;Shim,C.K.
  4. Deutsche Med. Wochen. v.110 Kurzzeit-Therapie des Ulcus duodeni mit Omeprazol und Ranitidin Classen,M.;Dammann,H.G.;Domschke,W.;Hengels,K.J.;Huttemann,W.
  5. Deutsche Med. Wochen. v.110 Abheilungstraten nach Omeprazol- und Ranitidin- Behandlung des Ulcus ventriculi Classen,M.;Dammann,H.G.;Domschke,W.;Huttemann,W.;Londong,W.
  6. Deutsche Med. Wochen. v.111 Unterschieldiche Heliungstendenz der Refluxosophagitis nach Omeprazol und Ranitidin Dammann,H.G.;Blum,A.L.;Lux,G.;Rehner,M.;Riechen,E.O.
  7. J. Kor. Pharm. Sci. v.23 Damage of omeprazole suppository on rectal mucosa of rats. Kim,H.J.;Han,Y.H.;Shim,C.K.
  8. Scand. J. Gastroenterol. v.20 no.SUP.108 Animal pharmacodynamics of omeprazole. A survey of the pharmacological properties of omeprazole in animals Larsson,H.;Mattsson,H.;Sundell,G.;Carlsson,E.
  9. Yakhak Hoeji v.37 Formulation of rectal suppositories of omeprazole Lee,C.H.;Hwang,S.J.;Oh,S.J.;Lee,G.J.
  10. Jpn. J. Pharmacol. Ther. v.19 Phase I study of omeprazole: Single-dose and multiple-dose studies Nakashima,M.;Kanamaru,M.;Hashimoto,H.;Takiguchi,Y.;Mizuno,A.;Kajiho,T.;Oka,T.;Matsuda,Y.
  11. Scand. J. Gastroenterol. v.20 no.SUP.108 Development of an oral formulation of omeprazole Pilbrant,A.;Cederberg,C.
  12. Scand. J. Gastroenterol. v.20 no.SUP.105 Pharmacokinetics and metabolism of omeprazole in animals and man-an overview Regardh,C.G.;Gabrielsson,M.;Hoffman,K.J.;Lofberg,I.;Skanberg,I.
  13. Therap. Drug Monitor. v.12 The pharmacokinetics of omeprazole in humans - a study of single intravenous and oral doses Regardh,C.G.;Gabrielsson,M.;Hoffman,K.J.;Lofberg,I.;Skanberg,I.
  14. J. Kor. Pharm. Sci. v.23 Effect of arginine or sodium phosphate dibasic on the stability of omeprazole in aqueous solution Shim,C.K.;Han,Y.H.;Woo,J.S.;Lee,C.H.
  15. Curr. Ther. Res. v.35 Omeprazole in the medical treatment of Zollinger-Ellison syndrome Vezzadini,P.;Tomassetti,P.;Toni,R.;Bonora,G.;Labo,G.
  16. Scand. J. Gastroenterol. v.20 no.SUP.108 The mechanism of action of omeprazole-a survey of its inhibitory actions in vitro Wallmark,B.;Lorenston,P.;Larsson,H.
  17. J. Pharm. Sci. v.83 First-pass metabolism of omeprazole in rats Watanabe,K.;Furuno,K.;Eto,K.;Oishi,R.;Gomita,Y.
  18. J. Pharmacobio. Dyn. v.4 A pharmacokinetic analysis program (MULTI) for microcomputer Yamaoka,K.;Tanigawara,Y.;Nakajima,T.;Uno,T.